Pilot Study of Bumetanide for Newborn Seizures: A Phase I Study of Pharmacokinetics and Safety of Bumetanide for Neonatal Seizures

Description of Study
This is a multicentre (Children’s, BWH and MGH and Tufts MC), randomized, double blind trial of Bumetanide for the treatment of refractory neonatal seizures. This pilot trial is designed to look at the safety and pharmacodynamics of Bumetanide in the term newborns with hypoxic-ischemic encephalopathy, focal or multi-focal stroke, or intracranial hemorrhage.

Inclusion Criteria 

Exclusion Criteria 

Expected number of eligible newborns in MGH 

We would expect to enroll 8-10 infants/year at MGH.